Product image of Myfortic (Mycophenolic Acid) supplied by GNH India

Myfortic

Active Ingredient:
Mycophenolic Acid
Origin:
EU

Myfortic (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Myfortic, is an antimetabolite immunosuppressant presented as an enteric‑coated tablet for oral use. It is used to prevent organ rejection in transplant recipients.

GNH India supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Manufacturer / TM Owner

Novartis Europharm Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Myfortic is an antimetabolite immunosuppressant used in transplantation to inhibit lymphocyte proliferation.

  • Renal transplantation: helps prevent graft rejection in kidney transplant patients.
  • Heart transplantation: helps prevent graft rejection in heart transplant patients.
  • Liver transplantation: helps prevent graft rejection in liver transplant patients.

How It Works

  • Myfortic delivers mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). This blockade reduces guanosine nucleotide synthesis, a critical step for DNA replication in activated T‑ and B‑lymphocytes, thereby suppressing their proliferation and dampening the immune response that leads to organ rejection.

Side Effects

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Diarrhea: frequent loose stools.
  • Abdominal pain: cramping or discomfort.
  • Headache: persistent or intermittent.
  • Tremor: fine shaking of hands.
  • Infections: increased susceptibility to common infections.

Serious or Rare Side Effects

  • Leukopenia: significant reduction in white blood cells.
  • Anemia: decreased red blood cell count.
  • Severe infections: opportunistic or life‑threatening infections.
  • Hepatic dysfunction: abnormal liver enzyme elevations.
  • Malignancy: increased risk of certain cancers.
  • Progressive multifocal leukoencephalopathy: rare brain infection.

Precautions & Warnings

Patients receiving Myfortic should be monitored closely for safety and efficacy.

  • Monitor blood counts: check complete blood count regularly.
  • Monitor renal function: assess serum creatinine and glomerular filtration rate.
  • Monitor liver enzymes: evaluate hepatic function periodically.
  • Pregnancy warning: avoid use during pregnancy (Category D) unless benefits outweigh risks.
  • Adjust in hepatic impairment: dose may need modification in liver disease.
  • Avoid live vaccines: immunosuppression can reduce vaccine effectiveness.
  • Store at ambient temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Myfortic may interact with several medicines, requiring dose adjustments or monitoring.

Major Interactions (Avoid)

  • Cyclosporine: increases mycophenolic acid exposure, raising toxicity risk.
  • Tacrolimus: similar increase in exposure, may require dose reduction.
  • Antacids/colestyramine: bind the drug and reduce absorption.
  • Rifampin: induces metabolism, markedly lowering drug levels.
  • Hormonal contraceptives: may reduce efficacy, consider alternative methods.

Moderate Interactions (Monitor Closely)

  • Azathioprine: additive bone‑marrow suppression, monitor blood counts.
  • NSAIDs: increased risk of nephrotoxicity, watch renal function.
  • ACE inhibitors/ARBs: potential for hyperkalemia, monitor electrolytes.
  • Live vaccines: reduced effectiveness, assess risk/benefit.
  • Proton‑pump inhibitors: may modestly affect absorption, observe clinical response.

Frequently Asked Questions

Myfortic is prescribed to prevent rejection of transplanted organs such as kidneys, hearts, and livers. It works by suppressing the immune system’s response that can attack the new organ, helping to maintain graft function and improve long‑term transplant outcomes.

Mycophenolic acid, the active component of Myfortic, blocks the enzyme inosine monophosphate dehydrogenase (IMPDH). This inhibition stops the synthesis of guanosine nucleotides needed for DNA replication in activated T‑ and B‑lymphocytes, thereby reducing their proliferation and dampening the immune response that leads to organ rejection.

The specific dose of Myfortic is determined by the prescribing clinician based on the patient’s transplant type, body weight, renal function, and other individual factors. Dosage adjustments are made according to therapeutic drug monitoring and clinical response.

Myfortic is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should be avoided during pregnancy unless the potential benefit justifies the risk. Limited data are available for breastfeeding; therefore, use while nursing is generally not recommended without specialist advice.

To place an order, submit an enquiry on the Myfortic product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Myfortic (mycophenolic acid) differs from calcineurin inhibitors such as cyclosporine or tacrolimus by targeting lymphocyte proliferation rather than cytokine production. It is often used in combination with calcineurin inhibitors to achieve synergistic immunosuppression while allowing lower doses of each agent, potentially reducing individual drug toxicity.

Myfortic tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Do not store in humid or excessively hot environments, and keep out of reach of children.

Myfortic is taken orally as an enteric‑coated tablet. The tablet should be swallowed whole with water, preferably on an empty stomach, unless the prescriber advises otherwise. The exact timing and frequency are set by the treating physician.

Serious risks include severe infections, leukopenia or anemia, hepatic dysfunction, and rare but life‑threatening conditions such as progressive multifocal leukoencephalopathy. Patients should be monitored regularly for blood count changes, liver enzyme elevations, and signs of infection.

Myfortic is contraindicated in patients with known hypersensitivity to mycophenolic acid or any tablet excipients. It should also be avoided in individuals with severe uncontrolled infections, active malignancy, or those who are pregnant without a clear benefit outweighing the risk.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mycophenolic Acid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT